On Monday, many investors drew an X next to the name of Nano-X Imaging(NASDAQ: NNOX), also known as Nanox. The next-generation medical imaging specialist experienced a sell-off following its latest earnings release that morning, and by the end of the day, its price had fallen by almost 5%. That didn't compare well to the S&P 500's (SNPINDEX: ^GSPC) 0.6% increase. Fourth-quarter results published Before market open, Nanox unveiled its fourth-quarter results, which showed that the company booked $3 million in revenue, which was an improvement over the $2.4 million it collected in the same period of 2023. On the bottom line, however, the specialty healthcare company's net loss deepened. It came in at $14.1 million ($0.23 per share), against the year-ago deficit of $10.2 million. Few analysts track Nanox stock. Regardless, according to data compiled by The Wall Street Journal, collectively they were anticipating a slightly narrower net loss of $0.22 per share. In its earnings release, Nanox attributed the deeper bottom-line shortfall to a one-time, $3 million income item that was booked in the third quarter. In more positive developments, Nanox provided a business update showcasing its two recent regulatory approvals. The first, earned in December, was the Food and Drug Administration's (FDA) nod for its Nanox.ARC, indicated for general use, and the second was the granting of a CE mark for the same system this past February. This is a quality designation required to sell products in most European countries. Holding steady Another development in Nanox's favor was its cash position. The company reported that it had cash, equivalents, and other fairly liquid assets totaling $83.5 million at the end of last year. This was slightly higher than the $82.8 million at the conclusion of 2023, indicating that management is doing a good job of conserving those precious resources. Don’t miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves: Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $284,402!* Apple: if you invested $1,000 when we doubled down in 2008, you’d have $41,312!* Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $503,617!* Story Continues Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon. Continue » *Stock Advisor returns as of March 24, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nanox Stock Slumped Today was originally published by The Motley Fool View Comments
Why Nanox Stock Slumped Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...